Boehringer Ingelheim GmbH and Singapore’s Agency for Science, Technology and Research (A*STAR) unveiled a global licensing agreement on 2 June under which the German pharma gets worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. BI will take over preclinical and clinical development of the antibodies, with A*STAR eligible for payments of up to €100m (about $107.3m) in upfront cash and development and commercialization milestones
BI said it aims to use the antibodies to develop a range of highly targeted cancer therapies using therapeutic-effector mechanisms...